摘要
目前,慢性肾脏病的诊断及预后缺乏准确性、敏感性,主要是受到特异性生物标志物的限制。早发现及预防并发症的发生,以提高生存率和生活质量为目标极为关键。尿液是探索肾脏疾病生物标志物的宝贵资源,近年来由于组学平台和生物信息学的迅猛发展,产生了许多关于肾纤维化的新型生物标志物的研究。基于尿蛋白质组学生物标志物的分类器CKD273与肾脏疾病和肾纤维化的严重程度有关,并已证明其在预测DKD及心血管事件的重大价值。CKD273具有肾脏病精准化治疗的里程碑意义,基于这个成功的例子,蛋白质组学有望发展成为指导精准化干预的关键技术。笔者回顾了过去10年尿蛋白质组学的重大发展,重点介绍了CKD273模型在慢性肾脏病中的应用进展。
At present,the diagnosis and prognosis of chronic kidney disease lacks accuracy and sensitivity,mainly due to the limitation of specific biomarkers.Early detection and prevention of complications are critical to improving survival and quality of life.Urine is a valuable resource for exploring biomarkers of kidney disease.In recent years,due to the rapid development of omics platforms and bioinformatics,many new biomarkers of renal fibrosis have been produced.The CKD273 classifier based on urine proteome biomarkers is related to the severity of kidney disease and renal fibrosis,and has proven to be of great value in predicting DKD and cardiovascular events.CKD273 is a milestone in the precise treatment of kidney disease.Based on this successful example,proteomics is expected to develop into a key technology to guide precise intervention.We reviewed the major developments in urinary proteomics over the past 10 years,highlighting the application of CKD273 in chronic kidney disease.
作者
徐耀
徐艳
刘昌华
XU Yao;XU Yan;LIU Changhua(Jiangsu Province Subei People’s Hospital,Clinical Medicine College,Yangzhou University,Yangzhou 225009,China)
出处
《中国医学创新》
CAS
2020年第22期165-169,共5页
Medical Innovation of China
